Browse All

Current Filters

CLEAR FILTER x

TITLE

CREXONT® (IPX203, ER CD-LD) Super-responders: Enhanced Symptom Control in Parkinson’s Disease

Author:Allard, Simon   Banisadr, Ghazal   Fisher, Stanley   LeWitt, Peter   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.003  

Author Institution:Amneal Pharmaceuticals, Baltimore, MD  Amneal Pharmaceuticals, Evanston, IL  Amneal Pharmaceuticals, Warren, NJ  Henry Ford Hospital - Franklin Pointe, West Bloomfield, MI  

Gender-based Differences in Parkinson’s Disease Hospitalization: A Nationwide and Single Center Study

Author:Xu, Zhimin   Bujala, Nishitha   Spirollari, Eris   Jiang, Andy   Al-Mufti, Fawaz   Fekete, Robert   

Session Name:P3: Movement Disorders: Parkinson's Disease Epidemiology  

Topic:Movement Disorders  

Program Number:P3.004  

Author Institution:Westchester Medical Center, Valhalla, NY  Westchester Medical Center, Elmwood Park, NJ  New York Medical College, Valhalla, NY  Westchester Medical Center, Stamford, CT  

Simplified Twice-daily CREXONT® Regimen Delivers Significant Gain in “Good On” Time in Parkinson’s Patients with Lower Levodopa Needs

Author:Allard, Simon   Fisher, Stanley   Bahroo, Laxman   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.004  

Author Institution:Amneal Pharmaceuticals, Baltimore, MD  Amneal Pharmaceuticals, Warren, NJ  Medstar Georgetown University Hospital, McLean, VA  

Paraquat Exposure and Parkinson’s Disease Risk in the United States: A Meta-analysis of Epidemiologic Studies

Author:Pitton Rissardo, Jamir   Fornari Caprara, Ana Leticia   Walker, Ian M.   

Session Name:P3: Movement Disorders: Parkinson's Disease Epidemiology  

Topic:Movement Disorders  

Program Number:P3.005  

Author Institution:Cooper University Hospital, NJ  Cooper University Hospital, Camden, NJ  

Effectiveness of Foslevodopa/Foscarbidopa in Subgroups of Patients Earlier within Advanced Parkinson’s Disease in an Interim Dataset of ROSSINI

Author:Aldred, Jason   Jost, Wolfgang   Bergquist, Filip   Evans, Andrew   Hassin-Baer, Sharon   Hauser, Robert   Henriksen, Tove   Malaty, Irene   Mestre, Tiago   Rodriguez Cruz, Ramon   Schwingenschuh, Petra   Simu, Mihaela   Bergmann, Lars   Caughlin, Sarah   Gopalkrishnan, Mallika   Kukreja, Pavnit   O’Meara, Marie   Parra, Juan Carlos   Shah, Megha   Mir, Pablo   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.005  

Author Institution:Selkirk Neurology & Inland Northwest Research, Spokane, WA  Parkinson-Klinik Ortenau, Wolfach, Germany  Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden  The Royal Melbourne Hospital, Parkville, Australia  Chaim Sheba Medical Center, Tel Hashomer, Israel  University of South Florida, Tampa, FL  Movement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark  University of Florida, Gainesville, FL  Division of Neurology, The Ottawa Hospital, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada  Neurology One, Orlando, FL  Medical University of Graz, Graz, Austria  University of Medicine and Pharmacy Timisoara, Timisoara, Romania  AbbVie Inc, Ludwigshafen, Germany  AbbVie Inc, IL  AbbVie Inc, North Chicago, IL  AbbVie Inc, Chicago, IL  Servicio De Neurologia. Hospital Virgen Del Rocio, Seville, Spain